Navigation Links
Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
Date:8/29/2008


Four-month study detailing effects of treatment of HIV-positive

individuals with American Biotech Labs (ABL) ASAP 10 treatment indicates

significant improvement in the condition of the subjects after treatment;

in-vitro laboratory work shows that ABL nanosilver particles can block

entry of the virus into cells, "eventually destroying the virus"

ALPINE, UT, Aug. 29 /PRNewswire-FirstCall/ - American Biotech Labs, developer of a new class of products based on the company's patented nano-catalytic SilverSol Technology(TM), today announced that a preliminary study of the effect of the company's ASAP 10 treatment on HIV-positive individuals has been published in the first issue of the Journal of the Science of Healing Outcomes (JSHO; http://www.thejsho.com/pdf/Effect.pdf). JSHO is a scholarly health journal that publishes compelling new medical research data and reports.

The study was conducted over four months with seven HIV-positive patients, each of whom was administered 15 ml of ABL ASAP 10 ppm (parts per million) four times daily. As a result of the ABL treatment, "Clinically, (the patients) were 100 percent fit and were feeling much better after the treatment period," said Dr. B.M. Hegde, world-renowned cardiologist and editor of JSHO.

During the course of the therapy, the patients experienced an average body weight gain of eight kilograms (17.6 pounds) and an average T-lymphocyte count increase of 180 per micro-liter (39.52 percent).

One of the study's most significant findings, said Hegde, was the effect of ABL ASAP on HIV, the AIDS-causing virus. "Our recent laboratory work of the effect of nano silver in vitro on the... virus did show that the nanosilver particles could bind to (HIV) and could potentially block the viral entry into cells, eventually destroying the virus."

Hegde added, "Now that we have the laboratory results
'/>"/>

SOURCE Clifton Mining Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
8. Symmetry Medical Reports Preliminary Third Quarter Revenue
9. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, Iceland ... provides comprehensive capabilities for using the genome to create better ... publication of the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around ... authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
(Date:3/25/2015)... , March 25, 2015 FDNA®, ... version 4 of Face2Gene, allowing geneticists around ... computers, as well as mobile devices. Face2Gene® facilitates detection ... malformations to present comprehensive and up-to-date genetic references. The ... Genetics Meeting, ACMG 2015, in Salt Lake ...
(Date:3/25/2015)... The global Smart Weapons Market can ... technology, platform, and geography. The various technologies ... infra-red, microwave, global positioning systems, and other ... systems, and inertial navigation systems. , Browse ... spread through 172 Pages and in-depth TOC ...
Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... the Way for the Phase III Clinical Development ... Commercialization of THR-100 in Developing Countries, ... (Euronext,Brussels: THR), a biotechnology company focused on vascular ... transfer to Bharat,Biotech International Limited (Hyderabad, India) for ...
... Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical ... products and high intensity focused ultrasound tumor,therapy systems, today announced ... - China Day. Location: ... ...
... 2 Sanofi-aventis announced,today that one year ... STEEPLE,studies confirm clear net clinical benefit for ... for Lovenox(R) vs,Unfractionnated Heparin (UFH). The ... were presented during,hotline sessions at the European ...
Cached Biology Technology:ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... NY) ─ Researchers at Albert Einstein College of Medicine of ... bacteria that cause tuberculosis (TB), a disease responsible for an ... the March 21 online issue of Nature Chemical Biology ... also prevent resistant TB strains from developing. "This approach ...
... (San Diego, CA) March 18, 2010 GenWay Biotech, ... launched the You Test YouTM Cancer Assessment is expanding this ... to offer the You Test YouTM Cancer Assessment in Greece ... other European nations as well. GenWay currently offers this ...
... RECAN has developed a range of unique and highly ... in the blood which counteract bacteria, viruses or cancerous ... of recombinant proteins which are important components of cellular ... in immunisation and experimental studies. A further key advance ...
Cached Biology News:Einstein researchers discover 2 new ways to kill TB 2Manufacturing antibodies 2Manufacturing antibodies 3
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
... assay kit provides complete components including positive ... of DNA fragmentation in cultured cells and ... labeling of apoptotic cells. Internucleosomal ... in mammalian cells. MBLs ApoDIRECT In Situ ...
... Life Science FLA-5100 imaging system allows imaging ... as 40 x 46cm at a pixel ... system is especially suitable for protein electrophoresis ... analysis for genomics., Fuji s FLA-5100 includes ...
... speed and excellent temperature uniformity. Protocols that ... can be run without any modifications. The ... for 48 or 96 wells. In addition, ... applications are available. The High Precision Smart ...
Biology Products: